Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation

Brian F. Gage, Andria B. Cardinalli, Douglas K. Owens

Research output: Contribution to journalArticlepeer-review

97 Scopus citations


Background and Purpose - Recent atrial fibrillation guidelines recommend the incorporation of patient preferences into the selection of antithrombotic therapy. However, no trial has examined how incorporating such preferences would affect quality-adjusted survival or medical expenditure. We compared 10-year projections of quality-adjusted survival and medical expenditure associated with two atrial fibrillation treatment strategies: warfarin-for- all therapy versus preference-based therapy. The preference-based strategy prescribed whichever antithrombotic therapy, warfarin or aspirin, had the greater projected quality-adjusted survival. Methods - We used decision analysis stratified by the number of stroke risk factors (history of stroke, transient ischemic attack, hypertension, diabetes, or heart disease). The base case focused on compliant 65-year-old patients who had nonvalvular atrial fibrillation and no contraindications to antithrombotic therapy. Results - In patients whose only risk factor for stroke was atrial fibrillation, preference-based therapy improved projected quality-adjusted survival by 0.05 quality-adjusted life year (QALY) and saved $670. For patients who had atrial fibrillation and one additional risk factor for stroke, preference-based therapy improved quality-adjusted survival by 0.02 QALY and saved $90. In patients who had atrial fibrillation and multiple additional risk factors for stroke, preference-based therapy increased medical expenditures and did not improve quality-adjusted survival substantially. The benefits of preference-flexible therapy arose from the minority of patients who would have had a longer quality-adjusted survival if they had been prescribed aspirin rather than warfarin. Conclusions - As do risks of stroke and of hemorrhage, patients' preferences help to determine which antithrombotic therapy is optimal. Preference-based treatment should improve quality-adjusted survival and reduce medical expenditure in patients who have nonvalvular atrial fibrillation and not more than one additional risk factor for stroke.

Original languageEnglish
Pages (from-to)1083-1091
Number of pages9
Issue number6
StatePublished - Jun 1998


  • Aspirin
  • Atrial fibrillation costs and cost analysis
  • Stroke prevention
  • Warfarin


Dive into the research topics of 'Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation'. Together they form a unique fingerprint.

Cite this